Welcome to our dedicated page for XPHYF news (Ticker: XPHYF), a resource for investors and traders seeking the latest updates and insights on XPHYF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XPHYF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XPHYF's position in the market.
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) has announced its feature in a NetworkNewsAudio broadcast, enhancing its visibility in the investment community. The broadcast highlights the progress of XPhyto’s North American GMP mescaline synthesis program, which is on schedule, supporting the company's psychedelic medicine initiative. CEO Hugh Rogers noted the significant market opportunity in producing pharmaceutical-grade psychedelics, which could improve treatment for mental health conditions such as depression and PTSD. The company is focused on regulatory approval and commercialization for European markets.
XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF) announced progress in its GMP mescaline synthesis program, achieving preliminary synthesis and initial batch production. Key developments include a modified synthesis process and ongoing work to establish GMP standard operating procedures. The company is poised to establish pharmaceutical-grade psychedelics for therapeutic use, highlighting a growing market for substances like mescaline, which is linked to improved mental health outcomes. XPhyto is also advancing its psilocybin production program in Germany and retaining all intellectual property.
XPhyto Therapeutics Corp. announces the launch of its rapid 25-minute COVID-19 PCR test, Covid-ID Lab, for sale in Germany starting May 25, 2021. The test delivers results quickly, combining the accuracy of PCR testing with the speed of antigen tests. Initially secured manufacturing capacity can be scaled based on demand. Pricing will be competitive with existing COVID-19 PCR products. The test aims to serve various sectors, including airports, pharmacies, and medical clinics, enhancing rapid diagnostic capabilities in Europe.
XPhyto Therapeutics announced advancements in its drug formulation programs, including the successful completion of a human pilot study for its Rotigotine transdermal patch aimed at treating Parkinson's disease. The results lead to a pivotal trial phase. Additionally, the company purchased land in Biberach, Germany, for a new drug manufacturing facility, enhancing its capabilities in commercialization. The facility will permit up to 3,000 m2 of manufacturing space, aligning with production demands and contract opportunities.
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) has launched a pilot project in Germany for its rapid COVID-19 PCR test, Covid-ID Lab. This test offers results in just 25 minutes and is being conducted in collaboration with Spitzweg Apotheke, a pharmacy in Langen. The project aims to optimize the mobile collection and processing of samples, enhancing accessibility for high-risk patients. The laboratory equipment is fully operational, and a sales launch in Europe is planned for Q2 2021. CEO Hugh Rogers emphasizes the project's significance as it transitions from concept to commercial use swiftly.
XPhyto Therapeutics Corp. has delivered 2,000 rapid PCR tests to an Israeli distributor for clinical evaluation and regulatory approval. This initiative targets government institutions and private healthcare providers in Israel and nearby countries. The Covid-ID Lab tests aim for commercial approval within 90 days, supported by prior European CE-IVD certification. The PCR tests require only a single thermal cycle, enhancing speed and minimizing contamination risk. The company also plans a sales launch in Europe for Q2 2021, while emphasizing no claims about curing COVID-19.
XPhyto Therapeutics Corp. has entered an agreement with a German pharmaceutical wholesaler for the logistics and distribution of its Covid-ID Lab, a 25-minute COVID-19 RT-PCR test. This partnership ensures compliance with regulations and effective distribution across Germany. The Covid-ID Lab test is designed to deliver rapid results with minimal equipment, aiming to reduce operational costs. XPhyto is targeting a sales launch in Europe by April 2021, marking a significant advancement in their commercialization strategy.
XPhyto Therapeutics Corp. has appointed Wolfgang Probst as COO and Manfred Buchberger as Head of Corporate Development for XP Diagnostics. Following the European CE-IVD approval of its Covid-ID Lab diagnostic product on March 18, 2021, the company is gearing up for distribution and sales. Probst, with experience in management consulting, will oversee global operations, while Buchberger, a veteran in medical diagnostics, will manage business development. The Covid-ID Lab is a rapid PCR test that simplifies operations, reduces costs, and enhances convenience.
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) announced the European approval of its point-of-care SARS-CoV-2 RT-PCR test, Covid-ID Lab. This rapid test offers results in 25 minutes, combining the speed of rapid tests with the accuracy of PCR diagnostics. XPhyto plans to launch the product in April 2021 and is engaged in discussions with potential distribution partners. The test requires only a 20-minute PCR cycle and works with widely available PCR instruments. The company aims to enhance brand recognition through a broadcast via NetworkNewsAudio.
XPhyto Therapeutics Corp. received CE Mark approval for its point-of-care SARS-CoV-2 RT-PCR test, Covid-ID Lab, which provides rapid results in 25 minutes. The test boasts high sensitivity with a detection limit of 104.73 c/PCR and 100% specificity against 19 respiratory pathogens. Designed for ease of use, it eliminates RNA extraction, minimizing contamination risks. Aiming for sales launch in Europe by April 2021, XPhyto is in talks with potential distribution partners. The Company emphasizes no claims regarding the test's ability to combat the COVID-19 pandemic.
FAQ
What is the market cap of XPHYF (XPHYF)?
